Sanofi continue to spend time and cash defending cases against...

Sanofi continue to spend time and cash defending cases against it from patients who suffer from permanent alopecia ie hair loss after being treated with taxotere for breast cancer. As it is still a high earning drug for Sanofi even allthough there are generics available Sanofi still has this issue. We know Starpharma's DEPDOXs a dendrimer version which in phase 2 trials is showing no alopecia even temporary. Sanofi would find it pretty easy to progress a dendrimer version of their drug to approval imo. Also it would provide a new patent for the drug taking them above the high side effect generics, something to consider imo as we reach near completion of DEP phase 2 trials with company announcing they are in negotiations with major Pharma ( as per qrtly report).